Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840800 | 0.83 | KMT2A (1.00) | KMT2AALDH1A1MEN1ALOX12NPSR1 | |
| SCHEMBL15840669 | 0.81 | KMT2A (0.74) | KMT2AALDH1A1MEN1ALOX12NPSR1 | |
| SCHEMBL10114911 | 0.80 | KMT2A (0.58) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL14424378 | 0.80 | KMT2A (0.58) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL15840597 | 0.79 | ALDH1A1 (1.00) | KMT2AALDH1A1MEN1ALOX12MAPT | |
| SCHEMBL14424790 | 0.78 | LMNA (0.62) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL10114550 | 0.78 | LMNA (0.62) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL15836689 | 0.78 | KMT2A (0.75) | KMT2AALDH1A1MEN1ALOX12NPSR1 | |
| SCHEMBL4067862 | 0.78 | KMT2A (0.69) | KMT2AALDH1A1MEN1KDM4ECYP1A2 | |
| SCHEMBL15840635 | 0.78 | RAB9A (0.73) | KMT2AALDH1A1MEN1ALOX12NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | KMT2A 3667/4885ALDH1A1 4348/4885MEN1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.